Back

Eli Lilly Raises Full-Year Sales Outlook After Weight-Loss Drugs Lift Q1 Results

Eli Lilly reported first-quarter earnings and revenue above estimates and raised its full-year sales outlook, citing strong demand for its weight-loss drugs as shares rose 5.5%.

Summary

Eli Lilly reported first-quarter earnings per share of $8.55 and revenue of $19.8 billion, beating analyst estimates of $6.97 and $17.6 billion, respectively. Following the results, LLY shares rose 5.5%. The company also raised its full-year sales outlook, saying first-quarter performance was supported by strong demand for its weight-loss drugs, underscoring the importance of obesity treatments to its revenue growth.

Terms & Concepts
  • Earnings per share: A company’s profit divided by its outstanding shares, used to measure profitability on a per-share basis.
  • Revenue: The total income a company generates from its business operations before expenses are deducted.
  • Weight-loss drugs: Prescription medicines used to treat obesity or support weight reduction, a fast-growing category that has become a major revenue source for some healthcare companies.